We have concluded our 11th fiscal year in June 2023, achieving record-breaking sales and net profits thanks to your continued support. In the previous fiscal year, we were responsible for various qualitative research projects in the Healthcare and IT/High Tech markets, conducting participant recruitment and interviews as follows. We deeply appreciate your contribution to our endeavors.
In no particular order below
Patients/carers (hemophilia, myasthenia gravis, pulmonary hypertension, IgA nephropathy, non-small cell lung cancer, primary cholangitis, Crohn’s disease, metastatic castration-resistant prostate cancer, amyotrophic lateral sclerosis, atopic dermatitis, heart failure, melanoma, etc.)
Nurses (neurology, wound care, ICU, HCU, cardiology, psychiatry, orthopedic surgery, surgery, obstetrics and gynecology, endocrinology, etc.)
Clinical laboratory technicians
Sleep specialist physician
Endocrine and metabolic physician
Pharmaceutical company drug discovery officers
Users of online collaboration tools (financial, government, accommodation, wholesale and manufacturing industries)
Users of online ticketing websites
Web browser users, etc.